Lung Cancer Screening: Current Status in the United States by Cortese, Denis A.
Diagnostic and Therapeutic Endoscopy, 1996, Vol. 2, pp. 181-183
Reprints available directly from the publisher
Photocopying permitted by license only
(C) 1996 OPA (Overseas Publishers Association)
Amsterdam B. V. Published in The Netherlands
by Harwood Academic Publishers GmbH
Printed in Singapore
Lung Cancer Screening: Current Status in the United States
DENIS A. CORTESE
Division ofThoracic Diseases, Mayo Medical School Mayo Clinic Jacksonville, Jacksonville, Florida
(Received July 3, 1995; infinalform December 21, 1995)
KEY WORDS: Sputum cytology, lung cancer, mortality, chest x-ray, lung cancer screening
INTRODUCTION
Screening with sputum cytology and chest x-ray had no
impact on mortality from lung cancer. This was the sur-
prising result of trials of the 1970s and early 1980s spon-
sored by the National Cancer Institute (NCI). The trials
were performed at Johns Hopkins Medical Center, the
Memorial Sloan-Kettering Medical Center, and the Mayo
Clinic (1-6). The result has generated significant contro-
versy and discussion ofthe implications ofthe use ofchest
x-ray and sputum cytology in clinical practice in the
United States.
NCI-SPONSORED TRIALS
ThetwoNCI-sponsored trialsperformed atJohnsHopkins
and Memorial Sloan-Kettering studied the impact of spu-
tumcytology every4months in addition to an annual chest
x-ray and compared it with a control group that had only
the annual chest x-ray (2-4). The study was designed to
determine the effect of sputum cytology on lung cancer.
The results at these two centers showed no difference in
mortality, strong evidence that sputum is ofno additional
value to the annual chest x-ray. There was a slight trend
for decreased mortality in the squamous cell carcinoma
group, but the design of the study was not intended to
specifically assess the impact of screening on any partic-
ular cell type. Rather, the studies were designed to deter-
mine the overall impact of sputum cytology on mortality
from lung cancer.
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The design of the Mayo Clinic study was different (5).
This study compared the impact of sputum cytology and
chest x-ray every 4 months compared with a standard rec-
ommendation of a yearly sputum test and a chest x-ray.
More cancers were identified in the group screened with
sputum cytology and chest x-ray every 4 months. More
cancers were of early stage and, therefore, more were re-
sected in the screened group. However, there was no dif-
ference in the mortality from lung cancerbetween the two
groups (7,8).
FromNovember 1971 through July 1983, a total of366
incidence cases of lung cancer were identified among the
patients enrolled atMayo. In thegroup thatreceived every
4-month chest x-ray and sputum cytology, there were 206
patients identified with lung cancer for an incidence rate
of5.5/1,000 years. In the control group, the group advised
to have an annual chest x-ray and sputum cytology, there
were 160 patients with lung cancer for an incidence rate
of 4.3/1,000 years.
Ofthe 206 patients in the screened group, 78 (38%) had
postsurgical stage I cancer and 5 (2%) had postsurgical
stage II cancer. Of the 160 patients in the control group
who had lung cancer, 40 (25%) had postsurgical stage I
while one had postsurgical stage II disease.
The distribution of cell types in the total 366 incidence
cases was fairly even between the screened and the con-
trol groups. In the screened group the distribution was:
squamous cell carcinoma, 68 (33%); adenocarcinoma, 61
(30%); large cell carcinoma, 29 (14%); and small cell car-
cinoma, 48 (23%). In the control group the distribution of
cell type was: squamous cell carcinoma, 51 (32%); ade-
nocarcinoma, 40 (25%); large cell carcinoma, 24 (15%),
and small cell carcinoma, 45 (28%). Itwas not anticipated
that there would be such a high incidence of adenocarci-
noma and small cell carcinoma with the proportionate de-182 D.A. CORTESE
crease in squamous cell carcinoma. Small cell carcinoma
is a disease not amenable to screening because of its rapid
progression. As wenow know, adenocarcinoma is not eas-
ily detectedby sputum cytology butwhen detectedby spu-
tum, it is often untreatable.
There was a difference in the number of patients who
underwent curative resection between the two groups. In
the screened group only 18 patients (9%) had the cancer
detected by sputum cytology alone, 15 underwent resec-
tion. Seventy-two patients (40%) had the cancer detected
by the 4-monthly chest x-ray and 45 ofthese patients were
resectable. Forty-three (21%) patients had the cancer de-
tected by an unplanned nonstudy chest x-ray and 27 still
had resectable cancer. Finally, 73 patients (35%) had their
cancer detected after they developed symptoms but only
7 cancers were resectable. Of the total 206 patients in the
screened group, 94 (46%) had resectable cancer. In the
control group of patients, 48 (30%) had their cancer de-
tected by chest x-ray and 36 of these had resectable can-
cer. Of the patients, 112 (70%) developed symptoms
before detection of the cancer and only 15 cancers were
resectable. Of the total 160 patients in the control group,
51 (32%) had resectable cancer.
There are at least four important observations from this
information. First, only 9% of patients in the screened
group had cancer detected by sputum cytology alone.
Second, more patients in the screened group underwent
resection because of the sputum cytology and the screen-
ing chest x-ray. Third, a smaller percentage of patients in
the screened group presented with symptoms at the time
ofdetection. Finally, the results in both the study and con-
trol groups show that less than 13% of patients have re-
sectable cancers when they present with symptoms (7,8).
In some aspects, screening for lung cancer appears to
have been a success. In the study group, there were more
lung cancers detected, they weremore localized and there-
fore, more likely to be resected for potential cure.
Theoretically, there should, have been a reduction in the
mortality from lung cancer in the study group compared
to the control group. The surprising finding was that the
death rates in the Mayo study were the same. In the four
monthly screened group, 122 patients died of lung cancer
for a death rate of 3.2/1,000 years. In the control group,
115 patients were identified as dying from lung cancer for
a death rate of 3.0/1,000 years. The death rates in both
groups related to all causes of death were similar at
24.9/1,000 years and 24.8/1,000 years in the study and the
control groups, respectively.
This unexpected result has intrigued physicians for the
past 15 years. Possible explanations for the failure of
screening to reduce mortality include: the size ofthe study
groups, the statistical power of the study, the distribution
of the cell types, overdiagnosis of clinically unimportant
cancers, statistical chance, and ineffective therapy.
There were a number of initial assumptions in the orig-
inal study that proved erroneous. Cytologic examination
ofthe sputum was expected to detect 30 to 33% of all lung
cancers, yet only 9% of the patients had cancer detected
by sputum cytology alone. A lower percentage of patients
had squamous cell carcinoma while a higher percentage
of patients had adenocarcinoma and small cell carcinoma
than anticipated. It was expected that mortality from lung
cancer would not be affected by an annual chest x-ray, yet
it appeared that the annual chest x-ray played the biggest
role in the detection of these cancers. It was expected that
deaths from lung cancer would be easy to determine and
identify, but this did not prove to be the case, particularly
in the control group. And finally, it was anticipated that
the number of lung cancers in the control group would
equal the number in the 4-monthly screened group.
The cell type has dramatic prognostic implications.
Squamous cell carcinoma and adenocarcinoma, even
when roentgenographically occult, behave as different
cancers (9). In squamous cell carcinoma, approximately
62% of patients will have positive sputum cytology. Up to
43% of those with abnormal sputum have been reported
to be x-ray occult. Squamous cell carcinoma, particularly
when x-ray occult, is resectable at a rate above 80%. X-
ray occult squamous cell carcinoma has proven to have
unexpected nodal disease in approximately 17% of pa-
tients (10). The 5-year survival for roentgenographic oc-
cult squamous cell carcinoma is more than 90%.
Adenocarcinoma is dramatically different (11). In adeno-
carcinoma, positive sputum is obtained in no more than
25% of the patients. Adenocarcinoma is very rarely
roentgenographically occult. When sputum cytology is
positive more than70% ofthe patients will have nodal dis-
ease. The 5-year survival ofpatients with adenocarcinoma
when the sputum cytology is positive is 0%. Small cell
carcinoma, ofcourse, is rapidly progressive andwhen spu-
tum cytology is positive, it is invariably at an advanced
stage. Therefore, the distribution of cell type in a patient
population will have a great impact on the ability of spu-
tum cytology to reduce mortality.
The possibility of overdiagnosis of lung cancer when it
was not clinically significant, was a concern in the Mayo
study. However, other studies indicate that lung cancer is
usually virulent. In an autopsy series published in 1968 of
3,286 patients, 26 unsuspected lung cancers were found
(12). Ofthese, nodal involvement was found in 57%. Most
of the cancers contributed to the patient’s death although
it was not suspected at the time of death. The conclusion
of these authors was that lung cancer was not likely to re-
main clinically latent for long (12,13).STATUS OF LUNG CANCER SCREENING IN THE UNITED STATES 183
A study ofthe survival ofpatients with stage I lung can-
cer who underwent surgery, versus a group who did not
have surgery, was published in 1992 (14). This study was
a review ofthe NCI-sponsored screening study at all three
institutions. There were 336 patients who had stage I lung
cancer. Of these patients, 45 did not have surgery for var-
ious reasons. The 5-year survival of patients with stage I
lung cancer after surgery was 70%. The 5-year survival
for patients with stage I lung cancer without surgery was
less than 4%. The conclusion was that stage I lung cancer
is likely to be progressive and that the 5-year survival was
significantly reduced without surgery. Another article re-
viewing the survival of patients with stage I lung cancer,
not surgically resected, comes from Japan (15). This was
based on the Japanese screening study between the years
1976 and 1981. The study was performed at 20 institu-
tions. There were 42 screen-detected and 27 sputum-de-
tected patients with stage I lung cancer who did not have
surgery. The median survival was 25 months in the pa-
tients who had the stage I cancer detected by the screen-
ing studies. The survival was only 13 months in the 27
patients who had symptom-detected stage I cancer. Lung
cancer mortality in these two groups of patients was 80%
in the screen-detected patients and 81% in the symptom-
detected patients. Therefore, it appears that overdiagnosis
is not a likely explanation since the mortality rate was the
same in both groups.
Could random chance explain the lack of difference in
mortality? A recent article reassessed the statistics of the
Mayo study (16). There was only a 0.98% difference in
the lung cancer detection rates: 4.46% in the study group
and 3.48% in the control group. If the cancer rates had
been the same in the two groups and ifthe same 85% mor-
tality rate had occurred in the control group, there would
havebeen amortality advantage ofscreening ataP 0.052
level. These authors state that the statistical power of the
Mayo lung project had a 90% probability to detect a mor-
tality reduction of 50%. However, the study had only a
40% probability to detect a mortality reduction ofless than
20% between the two groups.
CONCLUSIONS
With all this information, the only conclusions that can be
drawn from the NCI-sponsored studies are: 1) there are
insufficient data to conclude that chest x-rays are of no
value in lung cancer screening since all patients in all
groups in all three centers received chest x-rays, and 2)
there areno definite data that sputumcytology testing adds
to the chest x-ray in the screening and treatment for lung
cancer. As a result, the NCI is funding a new series of tri-
als in the United States. For these trials, patients (men and
women) between the ages of 60 and 74 will be enrolled.
The sample size will be 74,000 patients in each group for
a total of 148,000 patients. This study is to have a 90%
power to detect a reduction in mortality of 10%. These tri-
als are just getting underway; unfortunately we will have
to wait many years before the results are known. It is cer-
tain thatwe will learnmuch about lung cancerduring these
trials, and we hope it will benefit our patients.
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